#China #Beijing #Novogene #U.S. Department of Defense #Section 1260H

Novogene's Response to Erroneous Inclusion on U.S. 1260H List

On June 8, 2026, the U.S. Department of Defense mistakenly included Novogene Co., Ltd. in its Section 1260H list under the National Defense Authorization Act for Fiscal Year 2021. This designation has significant implications for the company, prompting swift action from Novogene to clarify its standing and address this error.

Background of the Situation

Novogene, a publicly traded biotechnology enterprise based in China, focuses on advancing genomics and improving life through innovative technologies. However, the company was incorrectly associated with military affiliations, which it firmly denies. In its official statement, Novogene emphasizes that it operates independently without any state control or ownership, stating, "We are not a Chinese military associated company."

The Significance of the 1260H List

The Section 1260H list is part of a framework put in place by U.S. law to identify companies that may pose a threat to national security due to their ties with the Chinese military. Being listed on this list can severely impact a company’s ability to operate, particularly in partnerships with U.S. entities. Consequently, Novogene's designation on this list not only misrepresents the company's true nature but also jeopardizes its relationships with global partners—including universities, hospitals, and pharmaceutical companies—who rely on Novogene's genomic solutions.

Company's Commitment to Resolving the Issue

In response to the inaccurate listing, Novogene has initiated a formal process to seek removal from the Section 1260H list. The company is actively engaging with relevant U.S. authorities to clarify the facts surrounding its business practices. As stated in their release, "We have proactively engaged with relevant U.S. authorities to clarify the facts and will take all necessary measures to protect our company and global stakeholders' legitimate rights and interests."

Proactive Measures and Future Actions

Novogene’s leadership has expressed its commitment to resolving this issue effectively. The goal is to ensure that the company can continue delivering high-quality genomic services without the cloud of misrepresentation. Furthermore, Novogene reassures its stakeholders that despite the current situation, its partnerships and operations around the world remain unaffected. The company remains devoted to its mission of supporting life sciences research and clinical markets, with plans to uphold all existing commitments.

Moving Forward

Despite the challenges posed by this erroneous designation, Novogene is determined to rectify the situation swiftly. The company has a track record of innovation and excellence in genomics, and it intends to maintain its progress in that field. By clarifying its position and reinforcing its independence, Novogene aims to safeguard not only its reputation but also the interests of the stakeholders it serves.

In conclusion, Novogene's rebuttal to the inaccurate listing reveals the importance of careful scrutiny in matters of national security and business integrity. As the situation unfolds, the biotechnology enterprise is poised to continue its significant contributions to global health and innovation, undeterred by this setback.

For ongoing updates regarding this matter, stakeholders and the public are encouraged to stay tuned to Novogene’s official communications.